This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

AcutePreventiveSafetyDosingDosingDosingMOASavings & SupportSavings
& SupportSavings & SupportFormulary CoverageResourcesResourcesProvider & Patient EducationPrior Authorization
Prescribing InformationIndicationsPatient InformationPatient Site
Nurtec ODT DosingNurtec ODT DosingDosing in 2 different ways to treat or help prevent migraine Acute

One 75 mg ODT, as needed, for the acute treatment of migraine with or without aura in adults.1


The maximum dose for acute treatment is one 75 mg tablet in 24 hours.1

 Preventive

One 75 mg ODT every other day for the preventive treatment of episodic migraine in adults.1


No titration and no loading dose necessary.1

The safety of using more than 18 doses in a 30-day period has not been established.1

For preventive treatment, 91% of patients taking rimegepant 75 mg (n=335/370) and 90% of patients taking placebo (n=335/371) were at least 90% adherent with EOD dosing, based on the average tablet use, in the pivotal clinical trial.2
Take on the go
No water needed and can be taken with or without food1
The ODT formulation may be helpful for patients who experience nausea and vomiting3
Tmax of 1.5 hours and elimination half-life of ~11 hours1*
EOD=every other day; ODT=orally disintegrating tablet.Store Nurtec ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).1 Tips for how to take Nurtec ODT Ready With dry hands, open the blister pack and peel back the foil over one tablet. Do not push it through the foil.1

Gently remove Nurtec ODT from the blister pack immediately before taking; do not store it for future use.1 Set Patients can place Nurtec ODT on or under their tongue, and it dissolves within seconds—no water needed.1 Go A single 75 mg tablet can be taken as needed for acute treatment and/or every other day for preventive treatment.1 Instructions for Use Click for full Instructions for Use. Help your patients get started
View dosing guide
 Download dosing guide Loading
Learn about financial assistance
 Savings & Support Loading
View prior authorization resources
 Resources LoadingHave samples of Nurtec ODT delivered to your office Get samples LoadingReferences:Nurtec ODT. Package insert. Pfizer Inc.Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60.Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. Get the details on savings and support Get savings information Loading Download the Nurtec ODT
dosing card ViewLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-NNT-USA-4379
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.
Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.